

245 Serious Generalized Skin Disorders

REFERENCES

1. Ayangco L, Rogers RS III: Oral manifestations of erythema multiforme. *Dermatol Clin* 21: 198, 2003.
2. Rzany B, Hering O, Mockenhaupt M, et al: Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. *Br J Dermatol* 135: 6, 1996.
3. Paquet P, Pierard GE: Erythema multiforme and toxic epidermal necrolysis: a comparative study. *Am J Dermatopathol* 19: 127, 1997.
4. Power WJ, Ghoraiishi M, Merayo-Llves J, et al: Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. *Ophthalmology* 102(11): 1669, 1995.
5. Weston WL, Morelli JG: Herpes simplex virus-associated erythema multiforme in prepubertal children. *Arch Pediatr Adolesc Med* 151: 1014, 1997.
6. Kakourou T, Klontza D, Soteropoulou F, Kattamis C: Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. *Eur J Pediatr* 156: 90, 1997.
7. French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. *Allergol Int* 55: 9, 2006.
8. Porteous DM, Berger TG: Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. *Arch Dermatol* 127: 740, 1991.
9. Kelemen JJ, Cioffi WG, McManus WF, et al: Burn center care for patients with toxic epidermal necrolysis. *J Am Coll Surg* 180: 273, 1995.
10. Roujeau JC, Kelly JP, Naldi L, et al: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. *N Engl J Med* 333: 1600, 1995.
11. Schöpf E, Stühmer A, Rzany B, et al: Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. *Arch Dermatol* 127(6): 839, 1991.
12. Sullivan JR, Shear NH: The drug hypersensitivity syndrome: what is the pathogenesis? *Arch Dermatol* 137: 357, 2001.
13. Wolkenstein P, Revuz J: Drug-induced severe skin reactions—incidence, management and prevention. *Drug Saf* 13(1): 56, 1995.
14. Tas S, Simonart T: Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome). *Dermatology* 206: 353, 2003.
15. The Working Group in Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome: Rationale and consensus definition. *JAMA* 269: 390, 1993.
16. Resnick SD: Staphylococcal toxin-mediated syndromes in childhood. *Semin Dermatol* 11: 11, 1992.
17. O'Loughlin R, Roberson A, Cieslak PR, et al: The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000–2004. *Clin Infect Dis* 45: 853, 2007.
18. Bisno A, Stevens D: Streptococcal infections of skin and soft tissue. *N Engl J Med* 334: 4, 1996.
19. Zimbelman J, Palmer A, Todd J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive *Streptococcus pyogenes* infection. *Pediatr Infect Dis J* 18(12): 1096, 1999.
20. Goh CL, Khoo L: A retrospective study of the clinical presentation and outcome of herpes zoster in a tertiary dermatology outpatient referral clinic. *Int J Dermatol* 36: 667, 1997.
21. Glesby MJ, Moore RD, Chaisson RE: Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. *Clin Infect Dis* 21: 370, 1995.
22. Mandal BK: Herpes zoster in the immunocompromised populations. *Indian J Dermatol* 51(4), 235, 2006.
23. Algren JT, Lal S, Cutliff SA, et al: Predictors of outcome in acute meningococcal infection in children. *Crit Care Med* 21: 447, 1993.
24. Sexton DJ, Corey GR: Rocky Mountain “spotless” and “almost spotless” fever: a wolf in sheep's clothing. *Clin Infect Dis* 15(3): 439, 1992.
25. Darville T: Gonorrhoea. *Pediatr Rev* 20: 4, 1999.
26. Miller KE: Diagnosis and treatment of *Neisseria gonorrhoeae* infections. *Am Fam Physician* 73: 10, 2006.
27. Updated Recommended Treatment Regimens for Gonococcal Infections and Associated Conditions—United States. Centers for Disease Control and Prevention; April 2007. Available at: <http://www.cdc.gov/std/treatment/2006/updated-regimens.htm>. Accessed March 2010.
28. Update to CDC's *Sexually Transmitted Diseases Treatment Guidelines, 2006*: Fluoroquinolones No Longer Recommended for Treatment of Gonococcal Infections. Centers for Disease Control and Prevention; April 2007. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5614a3.htm>. Accessed March 2010.
29. Dominguez A, Cardeñosa N, Izquierdo C, et al: Prevalence of *Neisseria meningitidis* carriers in the school population of Catalonia, Spain. *Epidemiol Infect* 127: 425, 2001.
30. Caugant DA, Hoiby EA, Magnus P, et al: Asymptomatic carriage of *Neisseria meningitidis* in a randomly sampled population. *J Clin Microbiol* 32(2): 323, 1994.
31. Anderson J, Berthelsen L, Bech Jensen B, Lind I: Dynamics of the meningococcal carrier state and characteristics of the carrier strains: a longitudinal study within three cohorts of military recruits. *Epidemiol Infect* 121: 85, 1998.
32. Algren JT, Lal S, Cutliff SA, Richman BJ: Predictors of outcome in acute meningococcal infection in children. *Crit Care Med* 21(3): 447, 1993.
33. Van de Beek D, de Gans J, McIntyre P, Prasad K, et al: Steroids in adults with acute bacterial meningitis: a systematic review. *Lancet Infect Dis* 4(3): 139, 2004.